292 filings
Page 2 of 15
8-K
osf5aokrd48nzsii
4 Aug 23
Other Events
4:49pm
8-K
rsua1adhen3r9180cjo
7 Jul 23
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
8:21am
8-K
yt7vcu4non6yrsb9l
30 Jun 23
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
4:05pm
424B5
dgqgc8 5sx
28 Jun 23
Prospectus supplement for primary offering
8:16pm
8-K
gdnjmv3
28 Jun 23
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
7:50pm
424B5
817y33ytn5efpfeftp
27 Jun 23
Prospectus supplement for primary offering
8:51pm
8-K
7kfersc2bxw3zy uf
26 Jun 23
Changes in Registrant's Certifying Accountant
5:01pm
S-8
1qzkk0 xithnemgq
23 Jun 23
Registration of securities for employees
4:35pm
8-K
8xkbnsz im72ky
13 Jun 23
Financial Statements and Exhibits
5:22pm
8-K
rbgty5k4a9uaji
8 Jun 23
Departure of Directors or Certain Officers
5:02pm
S-8
p6gvg3b5d01
8 May 23
Registration of securities for employees
6:41pm
8-K
2joo3 z1tbmm
8 May 23
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
7:05am
ARS
qxfdr3r3fw1 yom
21 Apr 23
Annual report to shareholders
5:24pm
8-K
sahis
13 Mar 23
Regulation FD Disclosure
6:01am
8-K
utr2z6
10 Mar 23
Regulation FD Disclosure
3:43pm
8-K
c71x9 oq2
27 Feb 23
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
7:05am
8-K
61d0yq5d4 wxebyc2
22 Feb 23
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop SunosiĀ® (solriamfetol) in Europe
7:05am